CPC A61K 31/4745 (2013.01) [A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/44 (2013.01); A61K 31/475 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5545 (2017.08); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 38/179 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01)] | 14 Claims |
1. A method for enhancing sensitivity of a subject to an anticancer drug, comprising administering to the subject a pharmaceutical composition containing, as an active ingredient, 1-(2-fluorophenyl)-4,6-dimethyl-1H,2H,3H-pyrrolo[3,2-c]quinoline represented by the following Formula 1 or a pharmaceutically acceptable salt thereof:
|